Showing 161-170 of 9369 results for "".
Chitotriosidase: Providing Confirmation of Sarcoidosis When ACE Fails
https://practicaldermatology.com/topics/clinical-case-reports/chitotriosidase-providing-confirmation-of-sarcoidosis-when-ace-fails/26642/Chitotriosidase: Providing Confirmation of Sarcoidosis When ACE FailsCannabinoid Photo-Rejuvenation: A Clinico-Pathologic Study
https://practicaldermatology.com/topics/feature/cannabinoid-photo-rejuvenation-a-clinico-pathologic-study/29188/In this study, we sought to assess the effectiveness of a novel topical formulation containing CBD isolate, resveratrol, thyme extract, caffeine, and lecithin in reversing photodamage over a 90-day treatment period.The Latest on Systemic Agents for Psoriasis: A Q&A With Jashin J. Wu, MD, FAAD
https://practicaldermatology.com/topics/psoriasis/the-latest-on-systemic-agents-for-psoriasis/29073/The pharmacologic pipeline continues to produce strong options for systemic treatment of psoriasis. Practical Dermatology® spoke with Editorial Board member Jashin J. Wu, MD, FAAD, Founder and CEO of the Dermatology Research and Education Foundation, to discuss the latest treatment considerations wiFirst Medication for Severe Frostbite; Biosimilar to Humira with Interchangeability Status Approved; Two Late-Stage AD Candidates Advance
https://practicaldermatology.com/series/dermwire-tv/first-medication-for-severe-frostbite-biosimilar-to-humira-with-interchangeability-status-approved-two-late-stage-ad-candidates-advance/20267/In this episode of DermWireTV, the first medication to treat severe frostbite is approved by the FDA; the first high-concentration biosimilar to Humira with interchangeability status will soon be available in the US; and two companies with late-stage atopic dermatitis candidates provide key updates.Hair Loss in Patients With Diverse Skin Tones
https://practicaldermatology.com/series/the-practical-dermatology-podcast/hair-loss-in-patients-with-skin-of-color/18194/In this first installment of a two-part episode of The Practical Dermatology Podcast, Brooke Jackson, MD, founder and owner of Skin Wellness Dermatology Associates in Durham, NC, and a dermatologic surgeon and dermatologist, speaks about hair loss in patients with diverse skin tones, the timing of hTips for Success with Fillers
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/tips-for-success-with-fillers/20149/Heidi Waldorf, MD offers tips for getting the best results possible with fillers. From how to evaluate what patients need to considering shapes and proportions, she offers hands-on advice to help achieve optimal outcomes. Plus, she discusses the importance of managing patient expectations.Identifying SCC Risk
https://practicaldermatology.com/topics/skin-cancer-photoprotection/identifying-scc-risk/20144/Sherrif Ibrahim, MD discusses the challenges of managing squamous cell carcinoma (SCC). Great steps have been made in clinical, pathological staging systems, but Dr. Ibrahim says it’s still difficult to determine what to do with borderline cases. He talks about the need to determine frequency and inUnderstanding and Addressing the Impact of Plaque Psoriasis Among Patients with Skin of Color
https://practicaldermatology.com/topics/psoriasis/understanding-and-addressing-the-impact-of-plaque-psoriasis-among-patients-with-skin-of-color/23763/Patients, physicians, and others are joining together to elevate the level of care for patients with skin of color who develop psoriatic disease.DermWireTV: Zoryve Approved; New SDPA President; Project Determi-Nation; Stelara for Pediatric PsA
https://practicaldermatology.com/topics/psoriasis/dermwiretv-zoryve-approved-new-sdpa-president-project-determi-nation-stelara-for-pediatric-psa/20115/FDA has approved Zoryve from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The novel formulation of roflumilast cream 0.3% is indicated for once-daily application. Stelara (ustekinumab) from Janssen is now approveDermWireTV: Vtama Approved; Monkey Pox; AbbVie Scholarship; LRP Pride in Dermatology
https://practicaldermatology.com/topics/psoriasis/dermwiretv-vtama-approved-monkey-pox-abbvie-scholarship-lrp-pride-in-dermatology/20097/Vtama (tapinarof) cream 1% from Dermavant is approved for the treatment of psoriasis in adults. Tapinarof is an aryl hydrocarbon receptor agonist. As a public health service, VisualDx is offering pictures of monkey pox and disease information to support clinical decision-making. Forty-five scholarsh